MDT vs RMD
MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries. RMD: ResMed is a leading provider of AI-powered, cloud-connected medical devices and software that revolutionize the management of sleep apnea and chronic respiratory conditions at home.
Side-by-side fundamentals
| Metric | MDT | RMD | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $93.35 | $231.52 | |
| Market cap as of 2026-08-24 | $119.5B | $33.4B | |
| P/E as of 2026-08-24 | 24.25 | 21.47 | RMD lower |
| PEG as of 2026-08-24 | 3.09 | 2.24 | RMD lower |
| Net margin as of 2026-08-24 | +13.2% | +26.9% | RMD higher |
| Gross margin as of 2026-08-24 | +65.8% | +61.1% | MDT higher |
| Operating margin as of 2026-08-24 | +17.8% | +33.4% | RMD higher |
| ROE as of 2026-08-24 | +9.8% | +23.9% | RMD higher |
| ROA as of 2026-08-24 | +5.2% | +17.6% | RMD higher |
| Debt / equity as of 2026-08-24 | 0.57 | 0.10 | RMD lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.4% | +9.8% | RMD higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +12.9% | RMD higher |
| Dividend yield as of 2026-08-24 | +3.5% | +1.2% | MDT higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.57 | 0.74 | |
| 1-year return as of 2026-08-21 close | +2.5% | -19.7% | MDT higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.